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Abstract
Therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene delivery is an attractive approach
to treat ischemia. VEGF remains localized around each producing cell in vivo, and overexpression of mouse
VEGF164 (mVEGF164) induces normal or aberrant angiogenesis, depending strictly on its dose in the micro-
environment in vivo. However, the dose-dependent effects of the clinically relevant factor, human VEGF165
(hVEGF165), are unknown. Here we exploited a highly controlled gene delivery platform, based on clonal
populations of transduced myoblasts overexpressing specific VEGF levels, to rigorously compare the in vivo
dose-dependent effects of hVEGF165 and mVEGF164 in skeletal muscle of severe combined immune deficient
(SCID) mice. While low levels of both factors efficiently induced similar amounts of normal angiogenesis, only
high levels of mVEGF164 caused widespread angioma-like structures, whereas equivalent or even higher levels
of hVEGF165 induced exclusively normal and mature capillaries. Expression levels were confirmed both in vitro
and in vivo by enzyme-linked immunosorbent assay (ELISA) and quantitative reverse-transcriptase polymerase
chain reaction (qRT-PCR). However, in vitro experiments showed that hVEGF165 was significantly more effective
in activating VEGF receptor signaling in human endothelial cells than mVEGF164, while the opposite was true in
murine endothelial cells. In conclusion, we found that, even though hVEGF is similarly efficient to the syngenic
mVEGF in inducing angiogenesis at lower doses in a widely adopted and convenient mouse preclinical model,
species-dependent differences in the relative activation of the respective receptors may specifically mask the
toxic effects of high doses of the human factor.
Introduction
Coronary artery disease and peripheral vascular dis-ease are a major cause of morbidity and mortality in
Western societies despite current medical and surgical treat-
ment (Norgren et al., 2007). Therapeutic angiogenesis aims at
inducing new blood vessels by the delivery of vascular
growth factors in order to increase the perfusion of tissue
distal to a vascular occlusion, and it is a promising strategy for
the treatment of many patients for whom there is currently no
effective surgical or medical treatment. Vascular endothelial
growth factor-A (VEGF) is the master regulator of angiogen-
esis (Carmeliet, 2003). VEGF gene therapy with different
vectors has been investigated in several clinical trials for both
peripheral and coronary artery disease. However, despite
initial positive results, placebo-controlled phase II studies
have not shown clear clinical efficacy (Gupta et al., 2009).
Retrospective analyses found that a crucial problem is the
difficulty to achieve sufficient angiogenesis in the target tissue
at safe vector doses (Yla-Herttuala et al., 2004; Gupta et al.,
2009; Karvinen and Yla-Herttuala, 2010), highlighting the
need to carefully determine the therapeutic window of VEGF
dose in vivo in order to increase efficacy of the treatments.
Human VEGF has been shown to effectively induce an-
giogenesis in many other species, including rodents, rabbits,
and pigs, thereby allowing clinically relevant questions to be
investigated in convenient animal models. In particular,
information about the dose-dependent toxic effects is fun-
damental to guide the design of clinical trials. It has been
shown that the uncontrolled expression of murine VEGF in
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rodent preclinical models by a variety of methods leads to
progressive vascular proliferation and eventually the growth
of angioma-like vascular tumors (Springer et al., 1998; Car-
meliet, 2000; Lee et al., 2000; Pettersson et al., 2000). However,
reports of similar consequences by the delivery of human
VEGF in rodent models have been very rare (Schwarz et al.,
2000), prompting the question of whether the human and
murine factors may have intrinsically different effects or
whether mouse models may not be reliable to determine the
dose-dependent toxicity of human VEGF.
The VEGF molecule exists as at least three major isoforms
of 120/121, 164/165, and 188/189 amino acids in mouse and
in man, respectively, which differ in the size of their heparin-
binding domain and therefore in their avidity for extracellular
matrix (Park et al., 1993). Elegant studies with transgenic mice
selectively expressing only one of the three isoforms showed
that, while VEGF120 and VEGF188 alone caused defective
vascular morphogenesis, with respectively excessive vessel
size and insufficient branching, or the reverse, VEGF164 could
induce physiological vascular networks even in the absence
of the other isoforms (Ruhrberg et al., 2002), making VEGF164/165
the preferred choice for therapeutic over-expression.
VEGF164/165 remains tightly localized in the extracellular
matrix (Park et al., 1993; Springer et al., 2003). Therefore,
heterogeneous levels in tissue do not average with each
other, and we have previously found that the induction of
normal or aberrant angiogenesis by mouse VEGF164 depends
strictly on the amount produced in the microenvironment
around each producing cell and not on the total dose (Ozawa
et al., 2004; von Degenfeld et al., 2006). The delivery of dif-
ferent titers of gene therapy vectors only influences the total
dose but cannot uncover the effects of specific microenvi-
ronmental expression levels. Therefore, in this study we took
advantage of a highly controlled platform for VEGF ex-
pression in mouse muscle (Ozawa et al., 2004; von Degenfeld
et al., 2006), based on clonal populations of transduced
myoblasts homogeneously producing specific factor levels to
rigorously compare the in vivo dose-dependent effects of
human and mouse VEGF164/165.
Materials and Methods
Vector construction
A bicistronic construct, carrying a truncated version of the
mouse CD8a gene the mouse VEGF164 gene linked to, was
generated. Formouse CD8 the truncated version Lyt-2, or Lyt-
2.2 (trCD8a), occurs naturally by alternative splicing, spanning
codons 1–222, and it includes the signal peptide, the full ex-
tracellular, and transmembrane regions, whereas the cyto-
plasmic region is truncated after the first two amino acids
(221–222) (Tagawa et al., 1986). The full retroviral construct
(mV) was generated by cloning the cDNAs encoding mouse
VEGF164 and mouse trCD8a upstream and downstream of an
encephalomyocarditis virus internal ribosomal entry sequence
(IRES). The control construct (mCD8) contained the IRES and
mouse trCD8a sequences but no sequence for VEGF.
Correspondingly, a similarly truncated version of the
human CD8 gene was generated by PCR from the full-length
transcript (a kind gift by Dan Littman), and the correspond-
ing constructs containing the genes for human VEGF165,
IRES, and trCD8a (hV), and the control construct containing
IRES and human trCD8a but no VEGF (hCD8) were cloned.
Cell culture
Primary myoblasts, isolated from C57BL/6 mice and al-
ready transduced to express the b-galactosidase marker gene
(lacZ) from a retroviral promoter (Rando and Blau, 1994),
were further transduced at high efficiency with the retroviral
constructs described above for four rounds of infection, as
previously described (Springer and Blau, 1997). Early passage
myoblast clones homogeneously expressing specific levels of
VEGF were isolated by randomly sorting single cells in 96-
wells, using a FACS Vantage SE cell sorter (Becton Dickinson,
Basel, Switzerland). Cells were cultured in 5% CO2 on dishes
coated with bovine skin collagen 1 (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany), with a growth medium con-
sisting of 40% F10, 40% low-glucose Dulbecco’s modified
Eagle’s medium (DMEM; Sigma-Aldrich), and 20% fetal bo-
vine serum (HyClone, Logan, UT) supplemented with 2.5 ng/
ml of basic fibroblast growth factor (FGF-2; Becton Dick-
inson), as previously described (Banfi et al., 2002).
CD8 detection by FACS
Expression of human trCD8a and mouse trCD8a was as-
sessed by staining-transduced myoblasts with specific APC-
conjugated antibodies under experimentally determined
optimal conditions, as previously described (Misteli et al.,
2010). The mouse anti-human CD8 (clone 3B5; Caltag La-
boratories Inc, Burlingame) was used at 0.5 lg of antibody/
106 cells, at a dilution of 1:50. The rat anti-mouse CD8 (clone
53-6.7; Becton Dickinson) was used at 0.8 lg of antibody/106
cells, at a dilution of 1:50. Data were acquired with a
FACSCalibur flow cytometer (Becton Dickinson) and ana-
lyzed using FlowJo software (Tree Star, Ashland, Oregon).
Human and mouse VEGF quantification by ELISA
The production of VEGF in cell culture supernatants was
quantified using species-specific VEGF immunoassay ELISA
kits (R&D Systems Europe, Abingdon, United Kingdom)
according to manufacturer’s instructions. One ml of fresh
medium was incubated on myoblasts cultured in a 60-mm
dish for 4 hr, then filtered and analyzed in duplicate. Results
were normalized by the number of cells and expressed as ng
of VEGF per 106 cells per day. At least four separate dishes of
cells were assayed for each clone.
Myoblast injection into severe combined
immune deficient mice
For the evaluation of angiogenesis in vivo, cells were
implanted into 6–8-week-old severe combined immune de-
ficient (SCID) CB.17 mice (Charles River Laboratories, Sulz-
feld, Germany) in order to avoid an immunological response
to myoblasts expressing xenogenic proteins. Animals were
treated in accordance with Swiss Federal guidelines for ani-
mal welfare, and the study protocol was approved by the
Veterinary Office of the Canton of Basel-Stadt (Basel, Swit-
zerland). Myoblasts were dissociated in trypsin and re-
suspended in phosphate-buffered saline (PBS) with 0.5%
BSA; 5· 105 myoblasts in 5ll were implanted by intramus-
cular injections into the posterior auricular muscle, midway
up the dorsal aspect of the external ear or into the tibialis
anterior muscle of the hind limb, using a syringe with a
291/2G needle.
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Tissue staining
In order to visualize the entire vascular network of the ear,
we performed intravascular staining with a biotinylated
Lycopersicon esculentum (tomato) lectin (Vector Laboratories,
Burlingame, California), which binds the luminal surface of
all blood vessels, as previously described (Ozawa et al.,
2004). Briefly, 4 weeks after myoblast implantation, mice
were anesthetized and lectin was injected intravenously
through the femoral vein. Four minutes later the thoracic
cavity was opened and the tissues were fixed by perfusing
the animal with 1% paraformaldehyde and 0.5% glutaral-
dehyde in PBS, pH 7.4 at 120mmHg of pressure via a can-
nula in the left ventricle. Ears were then removed, bisected in
the plane of the cartilage, and stained with X-gal staining
buffer (1mg/ml 5-bromo-4-chloro-3-indoyl-b-D-galactoside,
5mM potassium ferrocyanide, 0.02% Nonidet P-40, 0.01%
sodium deoxycholate, 1mM MgCl2, in PBS, pH 7.4). Lectin-
coated vessels were stained using avidin-biotin complex-
diaminobenzidine histochemistry (Vector Laboratories),
dehydrated through an ethanol series from 50% to 98%,
cleared with toluene (Fisher Scientific, Wohlen, Switzerland)
and whole-mounted on glass slides with Permount embed-
ding medium (Fisher Scientific, Wohlen, Switzerland). To
obtain limb muscle sections, animals were anesthetized and
tissues were fixed by perfusion of 1% paraformaldehyde in
PBS, pH 7.4 at 120mmHg of pressure via a cannula in the left
ventricle. The tibialis anterior muscle was harvested in one
piece, cryoprotected in 10% sucrose overnight, embedded in
OCT compound (Sakura Finetek, Torrance, California), fro-
zen in freezing isopentane and cryosectioned. Tissue sections
were then stained with X-gal (20 lm sections) or with H&E
(10 lm sections) as described previously (Rando and Blau,
1994). Further 10-lm sections were immunostained as de-
scribed previously (Ozawa et al., 2004). The following pri-
mary antibodies and dilutions were used: rat monoclonal
anti-mouse CD31 (clone MEC 13.3; BD Biosciences) at 1:100;
mouse monoclonal anti-mouse a-smooth muscle actin (a-
SMA) (clone 1A4; MP Biomedicals, Irvine, CA) at 1:400;
rabbit polyclonal anti-NG2 (Chemicon, Temecula, CA) at
1:200. Fluorescently labeled secondary antibodies (Invitro-
gen, Basel, Switzerland) were used at a concentration of 1:200.
Vessel measurements
Regions of myoblast engraftment were determined by iden-
tifying b-galactosidase-positive muscle fibers on whole-
mounted ears. Images were taken on an Olympus BX61
microscope. Vessel length density (VLD) was measured as de-
scribed previously (Ozawa et al., 2004). Briefly, the total vessel
length was manually traced on images taken in 3–6 fields of
vision per ear, divided by the area of the field of vision and
expressed inmm/mm2. Image analysis was performedwith the
AnalySIS D software (Soft Imaging System Gmbh, Mu¨nster,
Germany).
Isolation of proteins, genomic DNA and total RNA
in muscle tissue
Whole fresh mouse muscles were disrupted using a Qia-
gen Tissue Lyser (Qiagen, Hilden, Germany) in 500 ll of
PBS + 1% Triton X-100, supplemented with Complete Pro-
tease Inhibitor Cocktail (Roche), which was nondenaturing
for proteins and did not lyse nuclei. After centrifugation,
200 ll aliquots of the lysates were used for protein quantifi-
cation and ELISA analysis. The remaining supernatant (on
average 250ll) was used to extract total RNA with the all-
Prep DNA/RNA/protein Mini kit (Qiagen), after supple-
mentation with the denaturing buffer provided by the
manufacturer. The pellet containing the whole nuclei was
then disrupted and homogenized in the same lysis buffer
using the Qiagen Tissue Lyser. Genomic DNA was extracted
using the same kit following the manufacturer’s instructions.
Quantitative real-time PCR
Total RNA was reverse-transcribed into cDNA with the
Omniscript Reverse Transcription kit (Qiagen) at 37C for
60min. Quantitative real-time PCR (qRT-PCR) was per-
formed on an ABI 7300 Real-Time PCR system (Applied
Biosystems, Carlsbad, CA). In order to quantify both the
human VEGF165 and mouse VEGF164 transcripts and to
compare their expression, a unique set of primers and probe
sequences was designed with Primer Express software
3.0 (Applied Biosystems), based on a common sequence ex-
pressed by both the human and mouse VEGF retroviral
constructs: ExoV forward: 5¢-GCTCTCCTCAAGCGTATTC
AACA; ExoV reverse: 5¢-CCCCAGATCAGATCCCATACA;
ExoV probe: 5¢-FAM-CTGAAGGATGCCCAGAAGGTA
CCCCA-TAMRA. Furthermore, to detect the mouse VEGF
transcripts expressed from the endogenous gene, including
all isoforms, an additional set of specific primers and probe
sequences for the 5¢-UTR of the native mRNA were designed
with Primer Express software 3.0 (Applied Biosystems):
EndoV forward: 5¢-GACGGGCCTCCGAAACC; EndoV
reverse: 5¢-TGGTGGAGGTACAGCAGTAAAGC; EndoV
probe, 5¢-FAM-AACTTTCTGCTCTCTTGGGTGCACTGGAC-
TAMRA. The cycling parameters were: 50C for 2min,
followed by 95C for 10min and 40 cycles of denaturation at
95C for 15 seconds and annealing/extension at 60C for
1min. All primers were used at 400 nM, the ExoV probe at
400 nM, and the EndoV probe at 100 nM. Reactions were
performed in triplicate for each template, averaged, and nor-
malized to expression of the 18S housekeeping gene (Applied
Biosystem assay, Hs99999901_s1).
qRT-PCR was also performed on genomic DNA to quan-
tify the number of myoblasts engrafted after implantation by
measuring the amount of stably integrated LacZ retroviral
construct. A reference curve was constructed for each of the
different myoblast clonal populations with a 10-fold dilution
series between 1 and 106 cells, using which the DCt data of
each sample could be transformed into the corresponding
absolute cell numbers. LacZ primer and probe sequences and
reaction concentrations were previously published (Banfi
et al., 2012).
In vitro assay of endothelial cell activation
Human umbilical vein endothelial cells (HUVEC) were
used between passage 3 and 5 and cultured as described
previously (Witzenbichler et al., 1998). Mouse aortic endo-
thelial cells (MAEC) were obtained from E. Battegay (Uni-
versity Hospital of Zurich, Switzerland) and cultured in
high-glucose DMEM (Sigma-Aldrich) supplemented with
10% FBS (HyClone), 1mM sodium pyruvate (Gibco, In-
vitrogen), 0.1mM MEM Non-Essential Amino Acids (Gibco,
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Invitrogen), 2mM glutamine (Gibco, Invitrogen), 100U/ml
penicillin, and 100 lg/ml streptomycin (Gibco, Invitrogen).
HUVEC were seeded into gelatin-coated six-well cell cul-
ture plates at 4· 105 cells/well and grown to confluency for
3 days without further medium changes. MAEC were seeded
into six-well cell culture plates at 1.5 · 105 cells/well and
grown to confluency. Subsequently, cells were serum starved
and stimulated with 50 ng/ml of human VEGF-A165 or mouse
VEGF-A164 (R&D System) for 6 hr. Total RNA was extracted
using RNeasy kit (Qiagen) and reverse-transcribed into
cDNA with the Omniscript Reverse Transcription kit (Qia-
gen) according to the manufacturer’s instructions. Quantita-
tive real-time PCR (qRT-PCR) was performed on an ABI 7300
Real-Time PCR system (Applied Biosystems). As internal
standard, 18S gene expression levels were used for normali-
zation (TaqMan Gene Expression Assay, Hs99999901_s1,
Applied Biosystem). The change in expression of human
and mouse vascular cellular adhesion molecule-1 (VCAM1)
upon VEGF-A stimulation was measured using customized
TaqMan Gene Expression Assay Hs01003372_m1 and
Mm01320970_m1, respectively (Applied Biosystem).
Statistical analysis
Data are presented as means – standard error of the mean.
The significance of differences was evaluated using one-way
ANOVA with the Bonferroni correction for multiple com-
parisons. P < 0.05 was considered statistically significant.
Results
Generation of mouse and human VEGF-expressing
myoblasts
Primary mouse myoblasts, which already expressed LacZ
from a different retroviral construct (Rando and Blau, 1994),
were transduced with retroviruses expressing either mouse
VEGF164 (mV) or human VEGF165 (hV) genes, linked to a
truncated version of mouse or human CD8, respectively, as a
marker to determine transduction efficiency by FACS (Mis-
teli et al., 2010; Wolff et al., 2012) (Fig. 1A). Negative control
myoblasts expressed mCD8 or hCD8, but no VEGF. Trans-
duction efficiency was greater than 95% in all cases (Fig. 1B).
The average VEGF expression, measured by ELISA, was
78.2 – 2.6 ng/106 cells/day and 82.4 – 5.4 ng/106 cells/day
for the mV and hV populations, respectively.
In vivo angiogenesis by heterogeneous mouse
or human VEGF levels
The primary transduced hV and mV populations were
composed of cells expressing heterogeneous VEGF levels,
depending on the number and genomic location of inte-
grated vector copies. As shown in Figure 1C, 4 weeks after
implantation into auricular muscles of SCID mice (n = 8 per
cell type), neither mCD8 nor hCD8 control cells affected the
capillary networks around transduced fibers. On the other
hand, mV myoblasts caused the growth of large numbers of
aberrant, bulbous vascular structures, which correlated with
very limited stable engraftment of VEGF-expressing cells by
X-gal staining, as previously described (Ozawa et al., 2004).
Surprisingly, expression of similarly high and heterogeneous
levels of human VEGF165 by hV myoblasts induced a robust
increase in the density of homogeneous normal capillaries
around transgenic fibers, but no instances of aberrant vascular
structures could be detected in any of the implanted tissues.
Distribution of VEGF expression levels in the hV
and mV populations
In order to determine why the heterogeneous hV popu-
lation did not induce any aberrant angiogenesis, we asked
whether the distribution of human VEGF expression levels
by individual cells in the population might be different and
FIG. 1. Heterogeneous expression of human VEGF165 in-
duces only normal angiogenesis. (A) Maps of the bicistronic
retroviral vectors carrying the coding sequence of murine
VEGF (mVEGF164) or human VEGF (hVEGF165) and of a
truncated version of murine or human CD8a (tr.CD8a), linked
through an internal ribosome entry sequence (IRES). (B)
Heterogeneous and high levels of expression of the VEGF-
IRES-CD8 cassettes were detected by tracking mouse and
human CD8a (mCD8 and hCD8, respectively) by flow cy-
tometry in the primary populations of transduced myoblasts
(red curves) and compared to nontransduced cells (negative
control, green curves). (C) Whole-mount lectin staining
(brown) of blood vessels 4 weeks after implantation of CD8
control cells (Ctrl CD8) and VEGF myoblasts expressing
heterogeneous levels of either murine or human VEGF in the
auricularis posterior muscle (n = 5–8 for all groups). Myo-
blasts engraftment was tracked by X-Gal staining (blue).
Heterogeneous murine VEGF levels caused the widespread
growth of aberrant angioma-like structures, whereas hetero-
geneous human VEGF levels induced only morphologically
normal capillaries. Size bar = 50lm in all panels. Color images
available online at www.liebertpub.com/hgtb
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possibly skewed toward lower values than that of the mouse
VEGF myoblasts. Therefore, single cells were isolated to
obtain clonal populations, and their human VEGF produc-
tion was measured and compared to that of mouse VEGF by
similarly isolated mV clones, previously generated (Misteli
et al., 2010). Twenty-one hV clones were randomly isolated
by single-cell FACS-sorting and found to secrete a wide
range of hVEGF165 levels (5.4 – 0.9 to 254 – 39 ng/106 cells/
day). This range was similar to that of mVEGF164 production
by 15mV clones (0.8 – 0.1 to 142.55– 10 ng/106 cells/day).
Analysis of the distribution of VEGF levels showed that both
mV and hV populations secreted similarly spread levels over
a wide range, without an enrichment for specific levels in
either population (Fig. 2).
Microenvironmental dose-dependent angiogenesis
by mouse and human VEGF
To rigorously compare the dose-dependent effects of hu-
man VEGF165 to those previously described for mouse
VEGF164, hV and mV clones secreting matched VEGF levels
were selected and injected into the ear and leg muscles of
SCID mice. As shown in Figure 3A, clones were chosen that
produced either a low or a high mouse VEGF164 level, which
were previously shown to induce normal and aberrant an-
giogenesis in mouse muscle, respectively (Ozawa et al., 2004)
(mVlow = 40.5 – 4 ng/106 cells/day and mVhigh = 133.6– 13.4
ng/106 cells/day). Matching hV clones produced similar and
also higher levels of human VEGF165 (hVlow= 32.2– 2.8 ng/106
cells/day, hVhigh1= 129.9– 7.5 ng/106 cells/day and hVhigh2=
253.7– 44.8ng/106 cells/day). The stability of VEGF secretion
by the integrated retroviral constructs was periodically as-
sessed by ELISA during expansion in vitro of all selected clones
over at least 10 passages, corresponding to about 30 population
doublings. In agreement with our previous results (Ozawa
et al., 2004; Misteli et al., 2010), VEGF production was within
10% of reference levels during expansion, confirming that the
clones reproducibly secreted predictable amounts of VEGF.
The quantification of the amount of secreted human and
murine VEGF protein by ELISA requires the use of distinct
species-specific antibody pairs, which may affect the precise
comparison of VEGF production between the two families of
clones. Therefore, the relative expression levels of all selected
clones were independently quantified by qRT-PCR (n= 4 per
clone). A specific primer set was designed to recognize a viral
construct-specific sequence, which is identical in the human
and mouse expression cassettes, ensuring that results were
comparable between all transduced populations. These results
confirmed that in all cases the hV clones expressed similar or
higher VEGF levels than the correspondingmVclones (Fig. 3B).
As shown in Figure 4A, 4 weeks after implantation in ear
muscles, low levels of both human and mouse VEGF in-
duced robust angiogenesis, comprising only homogeneous,
normal capillaries. High mouse VEGF164 expression gave
rise to abundant aberrant vascular structures, as expected.
However, a similarly high level of hVEGF165 (clone hVhigh1)
induced only normal angiogenesis. Remarkably, even the
hVhigh2 clone, which secreted double the amount of human
VEGF165, did not induce any angioma-like structures, but
only normal and homogeneous capillary networks (Fig. 4A).
In the presence of high mouse VEGF164 expression, X-gal
staining again showed very limited stable engraftment of
VEGF-expressing myoblasts, contrary to the conditions in-
ducing normal angiogenesis. Interestingly, and in agreement
with our previously reported data (Ozawa et al., 2004; von
Degenfeld et al., 2006; Misteli et al., 2010), aberrant vascular
structures continued growing into macroscopic angiomas
FIG. 2. Distribution of VEGF levels in clonal populations of
myoblasts expressing murine or human VEGF. Single myo-
blast clones expressing either mouse or human VEGF were
isolated from the polyclonal populations and their VEGF
expression in vitro was quantified by enzyme-linked immu-
nosorbent assay (ELISA), showing that both populations had
a similar distribution of VEGF expression levels in individual
cells. White bars=murine VEGF (mV)-expressing myoblasts;
black bars =human VEGF (hV)-expressing myoblasts.
FIG. 3. Human and murine VEGF production by selected
clones. Five clones were selected: two clones expressing ei-
ther mouse (mVlow) or human (hVlow) VEGF at low levels
and three clones expressing either mouse (mVhigh) or human
(hVhigh1, hVhigh2) VEGF at high levels. In vitro VEGF ex-
pression was measured by ELISA (A) and further confirmed
by quantitative reverse-transcriptase polymerase chain re-
action (qRT-PCR) (B). **p < 0.01.
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after delivery of a high mouse VEGF164 level despite its
limited duration of expression, and we have previously
found that this growth still depends on VEGF signaling,
likely of endogenous origin (Ozawa et al., 2004).
The amount of angiogenesis induced in the different
conditions was quantified by measuring the vessel length
density (VLD) in the cell implantation areas (n = 4 – 7/group).
As shown in Figure 4B, low levels of both mouse and human
VEGF caused a similarly large increase in VLD compared to
control cells (106– 4 and 104– 5mm/mm2, respectively,
compared to 38 – 2 and 31– 6mm/mm2 with mCD8 and
hCD8 cells; p < 0.001). VLD in areas implanted with the
mVhigh clone was not significantly increased compared to
control areas (38 – 2mm/mm2), as normal networks were
replaced by large aberrant vascular structures, which show
heterogeneously dilated diameters, but do not contribute an
appreciable increase in vessel length. However, the normal
capillaries induced by both clones expressing high levels of
human VEGF165 significantly increased VLD compared to
control cells (79– 6mm/mm2 and 120 – 2mm/mm2 respec-
tively; p < 0.001) to an extent similar to that induced by low
VEGF levels.
Vascular maturation
We further analyzed the morphology and maturation of
vascular networks induced by specific levels of human and
mouse VEGF in the tibialis anterior (leg) muscles of SCID
mice. Four weeks after injection (n = 4/group), implanted
myoblasts, which expressed LacZ, were visualized by X-gal
staining (Fig. 5A). Similarly to the implantations in ear
muscles, stably engrafted transgenic fibers were found along
needle tracks with similar frequency in all muscles, except in
the presence of the angioma-like structures induced by high
levels of murine VEGF (white asterisks in Fig. 5A), where
only rare LacZ-positive single cells could be detected in the
areas of injection. As shown in Figure 5B, low levels of both
mouse and human VEGF caused an increased density of
normal pericyte-covered capillaries around the transduced
myofibers, compared to muscles implanted with control
cells, while high levels of mouse VEGF induced aberrant
angioma-like structures, devoid of pericytes and covered
with a thick smooth muscle layer. However, in agreement
with the results obtained in the ear muscles, expression of
similar or even higher levels of human VEGF165 only in-
duced normal pericyte-covered capillary networks and no
aberrant vascular structures (hVhigh2 clone shown in Fig. 5B).
In vivo kinetics of VEGF expression
Lastly, we sought to verify the possibility that the ex-
pression of human VEGF by the hVhigh clones could decrease
more rapidly than that of mouse VEGF by the mVhigh clone
after implantation in vivo, leading to a lower effective VEGF
production in the tissue. Therefore, VEGF protein and
mRNA levels were determined immediately after injection of
mVhigh, hVhigh1, and hVhigh2 clones in tibialis anterior mus-
cles, as well as at 7 and 14 days later (n = 4 per each group
and time-point). Exogenous VEGF expression was quantified
by qRT-PCR using the same primer set described above,
which recognizes a sequence specific for the viral expression
cassette and normalized by the relative myoblast engraft-
ment in each sample, so as to account for the variability in
cell death following injection. Myoblast engraftment in each
sample was quantified by measuring the amount of stably
integrated LacZ retroviral genomes by qRT-PCR and com-
paring this to a specific reference curve for each population.
As expected, total VEGF protein dropped significantly in all
cases during the first 7 days after implantation (Fig. 6A), as
FIG. 4. Human VEGF165 induces only normal angiogenesis
despite high levels of expression. (A) Whole-mount lectin
staining (brown) of vascular networks induced by control
cells (Ctrl CD8) and mV and hV clonal populations. Myo-
blast engraftment was tracked by X-Gal staining (blue). Four
weeks after myoblast implantation, low murine and human
VEGF levels induced only morphologically normal capillar-
ies. High murine VEGF levels gave rise to aberrant angioma-
like vascular structures, whereas even higher levels of human
VEGF (clone hVhigh2) induced only normal angiogenesis (n=
5–8 for all groups). Vessels in the human low VEGF panel
appear darker because they still contain some red blood cells.
Size bar=50lm in all panels. (B) Quantification of the vessel
length density (VLD) in vascular networks induced by the
selected clones. ***p< 0.001. Color images available online at
www.liebertpub.com/hgtb
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about 90% of the myoblasts do not engraft and the retroviral
promoter is down-regulated. However, despite a certain
variability, both protein and mRNA measurements con-
firmed that in vivo expression of human VEGF165 was similar
or higher than that of mouse VEGF164 at all time-points (Fig.
6A and B). The expression of endogenous VEGF was deter-
mined by qRT-PCR using specific primers spanning the 5¢-
UTR sequence, which is absent in the retroviral cassette, and
the results did not show any significant changes between
groups at all time-points (data not shown).
FIG. 5. High levels of human VEGF165 induce mature capillaries rather than angiomas. (A) Myoblast engraftment was
tracked by X-gal staining (blue) 4 weeks after implantation of control cells (Ctrl CD8) or mV and hV clones expressing low
and high VEGF levels. In the presence of angiomas (white asterisks) induced by high levels of mouse VEGF very few
myoblasts survived after 4 weeks, whereas in all other conditions consistent and stable engraftment was observed around the
implantation needle tracks. (B) Vascular structures induced in the areas of engraftment 4 weeks after implantation were
immunostained with antibodies against CD31 (endothelium, in red), NG2 (pericytes, in green), and SMA (smooth muscle
cells, in cyan) in frozen sections of implanted limb muscles. Low levels of both mouse and human VEGF induced normal
pericyte-covered capillaries and the aberrant angioma-like vascular structures caused by high mouse VEGF levels (white
asterisk) were covered by a thick layer of SMA + cells but no pericytes. However, even higher levels of human VEGF (clone
hVhigh2) gave rise only to mature capillaries, covered with normal pericytes positive for NG2 and negative for SMA. Size
bar = 500 lm in (A) and 50lm in (B). Color images available online at www.liebertpub.com/hgtb
FIG. 6. In vivo expression of
human VEGF165 persists at
similarorhigher levels than that
of mouse VEGF over 2 weeks.
In vivo expression by mV and
hV clones was quantified im-
mediately after cell injection
(Day 0), after 1 (Day 7), or 2
weeks (Day 14), both by ELISA
(A) andqRT-PCR (B) onwhole-
muscle extracts, confirming that
expression of hV clones was
similar or higher than the cor-
responding mV clone up to
2 weeks after implantation.
Exo. VEGF, exogenous vector-
derived VEGF; *p<0.05 and
**p<0.01 vs mVhigh.
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Efficacy of VEGF receptor signaling activation
by mouse and human VEGF
Finally, in order to determine the mechanism by which
human and mouse VEGF caused different effects at similarly
high doses, we asked whether the two factors had an in-
trinsically different efficiency in signaling through their
cognate receptors in mouse and human endothelial cells,
respectively. Therefore, MAEC and HUVEC were stimulated
with 50 ng/ml of either mouse VEGF164 or human VEFG165,
and the relative signaling activation was assessed by mea-
suring the induced expression of its direct target gene vas-
cular cell adhesion molecule-1 (VCAM-1) (Schweighofer
et al., 2009). As shown in Figure 7, both factors were simi-
larly efficient in driving VCAM-1 expression in syngenic
endothelial cells (25.5-fold for mouse VEGF and 20.7-fold for
human VEGF, compared to the unstimulated condition).
However, mouse VEGF was significantly more efficient than
human VEGF on mouse endothelial cells, and conversely
human VEGF was more efficient on human endothelial cells,
suggesting that human VEGF may display different dose-
dependent effects in a mouse model due to a lower efficacy
in activating signal transduction in mouse endothelial cells
compared to the syngenic mouse VEGF.
Discussion
By taking advantage of a highly controlled cell-based
platform for expression of specific VEGF levels in skeletal
muscle, we could rigorously compare the dose-dependent
effects of human and mouse VEGF165/164 in a widely em-
ployed murine preclinical model. Although human VEGF165
was similarly effective to mouse VEGF164 in inducing normal
angiogenesis at low doses, it differed dramatically from the
syngenic factor in the potential to cause the growth of ab-
errant angioma-like vascular structures at higher doses. In
fact, while clones expressing more than about 100 ng/106
cells/day of mVEGF164 invariably caused the appearance
of angiomas by 4 weeks, even 250 ng/106 cells/day of
hVEGF165 induced only the growth of physiological capillary
networks. However, our results shown in Figure 7 suggest
that this is unlikely to reflect a fundamental biological dif-
ference between the human and murine factors, but rather a
lower potency of human VEGF165 in stimulating the mouse
VEGF receptors and vice versa.
There are no studies directly comparing the effects of
human and syngenic VEGF in preclinical animal models.
Angioma formation has been reported extensively after
mVEGF164 expression in different murine tissues, such as
skeletal and cardiac muscle with skin and fat (Springer et al.,
1998; Lee et al., 2000; Pettersson et al., 2000; Ozawa et al.,
2004), in agreement with our results. On the other hand,
the induction of angiomas by over-expression of hVEGF165
has been described only rarely. There are no reports of
hVEGF165-induced angiomas in mouse tissues, while one
study (Schwarz et al., 2000) described the appearance of an-
giomas in the heart of rats after injection of a high dose of a
hVEGF165 plasmid (500lg DNA) in a single intramyocardial
injection, probably leading to a localized hotspot of very
strong expression. Rabbit VEGF165 shares a greater degree of
homology with the human sequence (14 amino acid [aa]
difference) compared with mouse VEGF164 (19 aa difference).
In the skeletal muscle of rabbits, delivery of a single high
dose of hVEGF165-expressing adeno-associated viral (AAV)
vectors (1011 particles) caused aberrant vascular growth, the
formation of functional arterio-venous shunts and muscle
fibrosis, but only after at least 6 months of sustained ex-
pression (Zacchigna et al., 2007; Karvinen et al., 2011). One
dose-escalation study investigated the effects of delivering
from 109 to 1011 viral particles of hVEGF165-expressing
adenovirus (AV) to rabbit skeletal muscle and found dose-
dependent differences both in vessel morphology and func-
tional improvement (Korpisalo et al., 2011). However, the
short duration of expression afforded by the immune clear-
ance of AV vectors prevented the evaluation of angioma
formation. In human clinical trials, where low vector doses
are dictated by safety concerns, only one study reported the
transient appearance of spider angiomas at a site down-
stream of the treated tissue after delivery of hVEGF165
plasmid (Isner et al., 1996).
But why did human VEGF show reduced efficacy selec-
tively in inducing aberrant angiogenesis and not also normal
vascular growth? In fact, low doses of both factors effectively
increased vessel length density by the same amount (Fig. 4B).
We recently found that therapeutic over-expression of VEGF
in skeletal muscle does not cause vascular growth by
sprouting, but rather through an initial vascular enlargement
FIG. 7. The efficacy of VEGF-R signalling by mouse and
human VEGF is species-specific. The induction of expression
of the VEGF-A target gene VCAM1 was measured by qRT-
PCR in human and murine endothelial cells (EC) after
stimulation with 50 ng/ml of either recombinant murine or
human VEGF (rmVEGF164 and rhVEGF165, respectively).
Results are shown as relative expression compared to the
control condition without VEGF stimulation (CTR). *p < 0.05.
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followed by intussusceptive remodeling and longitudinal
splitting (Gianni-Barrera et al., 2013). We also found that both
normal and aberrant angiogenesis are induced through the
same process in these conditions. However, high doses of
mVEGF164 cause a significantly greater initial enlargement
than lower doses and, while intussusception is initiated in
both cases, pillars fail to complete in the vessels of larger
diameter, leading to a failure to split into normal capillaries
and to the continued circumferential growth of affected
vascular segments into angioma-like structures. Therefore, it
is possible to envision that a reduced efficacy of hVEGF165 in
activating mouse VEGF receptor signaling may lead to lesser
vascular enlargement and allow successful completion of
intussusceptive remodeling despite higher VEGF doses,
thereby avoiding the growth of aberrant angioma-like
structures. On the other hand, at lower doses, which allow
vascular splitting to complete successfully in either case, the
different potency of the two factors would not produce evi-
dent consequences on either the morphology or amount of
induced vessels.
It is clear that hVEGF165 is capable of inducing angioma
growth also in animal models if expressed at a sufficiently
high level and a prolonged time. Therefore, our findings
can in no way be taken as evidence that a tight control of
VEGF levels would not be required in a clinical application
of hVEGF165. Rather, they have implications for the pre-
clinical evaluation of VEGF-based strategies to treat ische-
mic conditions. In fact, it has been recognized that the
complexity of growth factor dosing may be pivotal for
the lack of efficacy in VEGF gene therapy clinical trials
(Yla-Herttuala et al., 2004), and it has been advocated
that preclinical development of vectors should include
the routine analysis of ‘‘STED’’ parameters: (1) Spread
through the tissue; (2) transfection efficiency; (3) expression
strength; and (4) duration of expression (Yla-Herttuala,
2006). Within this framework, our data suggest that, in a
preclinical animal model, parameter ‘‘E’’ will depend not
only on the amount of factor produced but also on the
species-dependent potency of the human protein in that
animal model. Therefore, the results of preclinical dose-
escalation studies of the human factor in animal models
should be interpreted with caution, as species-specific dif-
ferences may specifically mask important dose-dependent
side effects.
In conclusion, our data suggest that only dose-finding
Phase-I clinical studies can accurately determine the safety
profile of VEGF gene therapy approaches. In this respect, it
would be advantageous to employ a tool that allows the
controlled delivery of increasing doses, while also ensuring a
homogeneous distribution of expression levels in vivo, in
order to avoid hotspots and exploit the therapeutic window
of VEGF (Banfi et al., 2005). We recently developed such a
tool for cell-based VEGF gene delivery, whereby high-
throughput FACS purification of transduced progenitors al-
lows the rapid generation of populations homogeneously
expressing a pre-defined VEGF level (Misteli et al., 2010;
Wolff et al., 2012).
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